83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS metastasesMedian progression free survival (PFS) of 4.1 months in ADC resistant patients - double the PFS of patients in similar studies1,2,3Clinical benefit rate of 55% in evaluable patients includes HR+, HER2+ and TNBC disease - much higher than comparable studies1,2,3 PHILADELPHIA and VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ ...

PHILADELPHIA and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced it has closed its previously announced registered direct offering with healthcare-focused institutional investors and a certain existing investor and a director of the Company for the purchase and sale of 2,402,935 common sh ...

Core Viewpoint - BriaCell Therapeutics Corp. has announced a securities purchase agreement to raise approximately $5.0 million through the sale of common shares and warrants, aimed at funding working capital and research initiatives, including a Phase 3 study in advanced breast cancer [1][2]. Group 1: Offering Details - The company will sell 2,402,935 common shares and warrants at a price of $2.00 per share for institutional investors and $2.215 for an existing investor and a director [1]. - The warrants will have an exercise price of $2.11 per share, becoming exercisable six months post-issuance and expiring five years from the initial exercise date [1]. - The closing of the offering is expected around May 17, 2024, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital, general corporate purposes, research and development studies, and legal costs associated with the Phase 3 study in advanced breast cancer [2]. - The company may also consider repurchasing certain issued shares and warrants with the proceeds [2]. Group 3: Regulatory and Compliance Information - The offering is being conducted under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission on January 22, 2024, and declared effective on January 31, 2024 [3]. - A prospectus supplement detailing the offering terms will be filed with the SEC and made available on their website [3]. - The company is relying on exemptions from certain prospectus requirements under Canadian securities laws for the offering [3]. Group 4: Related Party Transactions - A director of the company may participate in the offering, which is classified as a "related party transaction" under Multilateral Instrument 61-101 [5]. - The company is exempt from the formal valuation requirement as the director's participation is not expected to exceed 25% of the market capitalization [5].

Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MDTwo poster presentations include Drs. Hurvitz (Fred Hutchinson Cancer Center), Brufsky (UPMC), and Cristofanilli (Weill Cornell) as authors PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleas ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol Name of each exchange on which registered Common shares, no par value BCTX The Nasdaq Stock Market LLC Warrants to purchase common shares, no par value BCTXW The Nasdaq Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE S ...

Core Insights - BriaCell Therapeutics Corp. will present three posters at the 2024 American Association for Cancer Research (AACR) Annual Meeting from April 5-10 in San Diego, CA [1] Group 1: Poster Presentations - Poster 1 focuses on the efficacy of the Bria-IMT regimen in inducing regression of CNS metastasis, scheduled for April 9, 2024 [1] - Poster 2 discusses the efficacy and safety of SV-BR-1-GM after progression on ADC in metastatic breast cancer patients, also on April 9, 2024 [1] - Poster 3 presents the Bria-OTS immunotherapy platform, which aims to harness gene-modified tumor cells for precision anti-tumor responses, scheduled for April 10, 2024 [1] Group 2: Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care [2]

Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell's pivotal Phase 3 study Disease control rate of 50% in evaluable patients treated with the Phase 3 formulation who failed prior antibody-drug conjugate (ADC) therapyNotable responder had failed 4 prior therapies including ADC therapy with metastatic liver tumor "no longer observed" following BriaCell treatment PHILADELPHIA and VANCOUVER, British Columbia, Feb. 07, 2024 (GLOBE NEWSWIRE) -- BriaCel ...

Bria-Pros+ is based on BriaCell's next generation personalized immunotherapy platformBria-Pros+ is capable of activating multiple types of immune cells, including helper T cells, cytotoxic (killer) T cells and natural killer cellsInitiation of GMP manufacturing represents a major milestone for BriaCell's off-the-shelf personalized cellular cancer vaccines PHILADELPHIA and VANCOUVER, British Columbia, Feb. 06, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" o ...

Core Points - BriaCell Therapeutics Corp. held its annual general meeting of shareholders on January 30, 2024, with 5,375,071 common shares voted, representing 33.63% of the total issued and outstanding shares [1][2]. Shareholder Resolutions - Shareholders voted overwhelmingly in favor of all proposed resolutions, including the re-appointment of MNP LLP as auditors and the election of directors [2]. - The following directors were elected with significant support: - Dr. William V. Williams: 3,487,704 votes (99.71% for) - Mr. Jamieson Bondarenko: 3,302,543 votes (94.41% for) - Mr. Marc Lustig: 3,221,128 votes (92.09% for) - Dr. Jane A. Gross: 3,491,308 votes (99.81% for) - Dr. Rebecca Taub: 3,491,351 votes (99.81% for) - Mr. Vaughn C. Embro-Pantalony: 3,489,398 votes (99.76% for) - Mr. Martin E. Schmieg: 3,486,913 votes (99.68% for) [3]. Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [4].

Financial Performance - For the three-month period ended October 31, 2023, total operating expenses amounted to $8,503,028, a significant increase from $5,403,151 in the same period of 2022[80] - Net financial income for the three-month period was $14,461,900, a substantial increase from $4,296,610 in 2022, driven by a gain of $14,282,078 from changes in warrant liability[87] - The Company reported a profit of $5,958,872 for the three-month period ended October 31, 2023, compared to a loss of $1,106,541 in the same period of 2022[88] - The Company's net cash used in operating activities for the period ended October 31, 2023, was $7,605,245, compared to $3,542,382 for the same period in 2022[93] Research and Development - Research and development costs for the same period were $6,857,257, up from $3,255,215 in 2022, primarily due to increased clinical trial expenses[82] - Clinical trial expenses surged to $5,397,438 in 2023 from $2,041,939 in 2022, reflecting the expansion of the Bria-IMT™ trial[85] - BriaCell is advancing its Bria-IMT™ targeted immunotherapy in a pivotal Phase 3 study, reporting a median overall survival of 13.5 months for patients, compared to 6.7-9.8 months in literature[74] Assets and Capital - As of October 31, 2023, total assets were $18,619,235, down from $27,163,577 on July 31, 2023, with a positive working capital balance of $17,361,478[89] - The Company has working capital of $17,361,478, down from $25,147,050 on July 31, 2023[91] - The accumulated deficit as of October 31, 2023, is $74,560,688, reduced from $80,652,231 on July 31, 2023[91] - The Company intends to raise additional capital through debt or equity financing to support its business plan objectives[92] Cash Flow - Cash and cash equivalents decreased by $7,605,245 from the previous year, reflecting a significant cash outflow[93] Ownership and Transactions - The Company completed a spinout transaction on August 31, 2023, resulting in a 2/3rd ownership of BriaPro Therapeutics Corp., which holds certain pipeline assets[75] Risk Management - The Company does not use derivative instruments to mitigate foreign currency risk, which arises from transactions in Canadian Dollars[96] - A 5% fluctuation in the Canadian dollar against the US dollar would not have a material effect on the total loss and comprehensive loss as of October 31, 2023[100] - The Company has no significant concentration of credit risk arising from operations, indicating a remote credit risk concentration[97] Accounting Policies - The Company has not adopted any new accounting policies during the period ended October 31, 2023[95] General and Administrative Expenses - General and administrative expenses decreased to $1,645,771 in 2023 from $2,147,936 in 2022, mainly due to lower non-cash share-based compensation[86]